27
total announcements
APLLTD.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 27 Oct 2026
Market Cap
₹15,079 Cr
P/E (TTM)
21.8
P/E (Forward)
15.7
EPS (TTM)
₹35.27
52W Low
₹635.30
52W High
₹998.00
Dividend Yield
1.58%
Beta
0.32
Price / Book
2.7
Debt / Equity
25.2
Revenue (TTM)
₹7,784 Cr
Gross Margin
70.56%
Operating Margin
10.89%
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has received USFDA Final Approval for Valganciclovir for Oral Solution, 50 mg/mL, marking its 227th final approval from the USFDA.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has informed about the incorporation of its wholly-owned subsidiary Alvesta Pharmaceuticals FZCO in Dubai, UAE, as per Regulation 30 of SEBI LODR Regulations, 2015.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Limited has received USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%, with an estimated market size of US$110 million for twelve months ending June 2026.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has made an announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding a newspaper advertisement for a special window for transfer and dematerialisation of physical securities.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has submitted a Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter and half year ended 30th September, 2026, confirming the dematerialisation of securities and listing on stock exchanges.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from DSP Trustee Pvt Ltd & Others.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has announced the closure of its trading window for dealing in securities from 1st October, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending 30th September, 2026, in compliance with SEBI regulations.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) following the inspection at its Bioequivalence Facility in Vadodara, Gujarat, which was conducted from 3rd March, 2025 to 7th March, 2025. The inspection has been closed.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has scheduled one-to-one meetings with investors and analysts on September 1-2, 2026, in Mumbai and virtually. No unpublished price-sensitive information will be shared during the meetings.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has scheduled one-to-one meetings with investors and analysts on September 1-2, 2026, in Mumbai and virtually. No unpublished price-sensitive information will be shared during the meetings.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has announced that certain equity share certificates have been transferred to the Investor Education and Protection Fund (IEPF) Authority due to being reported lost or misplaced. The company has published a notice in newspapers to inform shareholders about the transfer and to claim duplicate share certificates.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has appointed Mr. Chirag Shukla as its Company Secretary and Compliance Officer, effective August 20, 2026, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has announced the opening of a special window for transfer and dematerialization of physical securities, allowing shareholders to transfer and dematerialize their physical securities which were sold/purchased prior to 1st April, 2019.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has announced the resignation of Ms. Manisha Saraf as Company Secretary & Compliance Officer, effective August 10, 2026.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd reported a strong Q1 FY27 with 26% YoY revenue growth, driven by growth across all major businesses, including a 7% growth in India branded business, 37% growth in International Generics, and 33% growth in API business. The company's external environment remains competitive with pricing pressure, regulatory expectations, and geopolitical uncertainties.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has announced the voting results of its 16th Annual General Meeting (AGM) held on August 5, 2026. The meeting was conducted through video conferencing, and the voting results show that all resolutions were passed with significant majority. The company also declared a dividend on equity shares for the financial year 2025-26.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd held its 16th Annual General Meeting on 5th August, 2026, through video conferencing, where the company's audited financial statements for the year ended 31st March, 2026, were adopted, and a dividend on equity shares for the financial year 2025-26 was declared. The meeting also approved the appointment of a new independent director and ratified the remuneration to the cost auditors for the financial year 2026-27.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended 30th June, 2026, with a total income from operations of ₹2,149.77 crores and a net profit of ₹221.86 crores.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd has submitted the audio recording of its post-results conference call on August 4, 2026, which can be accessed on the company's website.
Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd reported its consolidated financial results for the first quarter ended 30th June 2026, with revenue from operations increasing by 26% YoY to Rs.2150 Cr, and EBITDA pre R&D increasing to Rs. 523 Cr; margin stood at 24%. The company's performance was driven by healthy volume growth, successful new product launches and continued execution across key markets.